Pegasparaginase-Based Chemotherapy Regimen vs L-Asparaginase–Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and Safety of a Pegasparaginase-Based Chemotherapy Regimen vs an L-asparaginase-Based Chemotherapy Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-Cell Lymphoma: A Randomized Clinical Trial
JAMA Oncol 2022 Jun 16;[EPub Ahead of Print], X Wang, L Zhang, X Liu, X Li, L Li, X Fu, Z Sun, J Wu, X Zhang, J Yan, Y Chang, F Nan, Z Zhou, X Wu, L Tian, M Ma, Z Li, H Yu, L Zhu, Y Wang, C Shi, X Feng, J Li, M Ding, J Zhang, M Dong, H Xue, J Wang, L Zou, L Su, J Wu, L Liu, H Bao, L Zhang, Y Guo, S Guo, Y Lu, KH Young, W Li, M ZhangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.